CGEM
Cullinan·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 1
Consensus Rating "Strong Buy"
Ample Liquidity
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About CGEM
Cullinan Therapeutics, Inc.
A biopharmaceutical company focused on developing a diversified pipeline of targeted therapies for patients with cancer
One Main Street, Suite 520, Cambridge, MA 02142
--
Cullinan Therapeutics, Inc., is incorporated in Delaware. The company is a biopharmaceutical company focused on developing a diverse pipeline of tumor-targeted therapies and immuno-oncology therapies with translational potential for cancer patients.
Company Financials
EPS
CGEM has released its 2025 Q3 earnings. EPS was reported at -0.77, versus the expected -0.89, beating expectations. The chart below visualizes how CGEM has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
